The ongoing Phase I study at University Hospital, Lille, aims to evaluate the safety and efficacy of CD19 CAR-T cell therapy in patients with refractory/relapsed acute myeloid leukemia (AML) expressing CD19. Given the high unmet medical need in this patient population, particularly for those with the t(8;21) translocation, successful outcomes could position this therapy as a viable treatment option, potentially capturing a significant share of the AML market. The competitive landscape includes existing therapies such as bispecific monoclonal antibodies targeting CD19, but CAR-T therapies may offer a more durable response. The study's results could influence future investment and partnership opportunities, particularly with stakeholders interested in advanced cellular therapies.